Why Chemotherapy That Costs $70,000 in the U.S. Costs $2,500 in IndiaThomas Bollyky
Apr. 14, 2013
1.Trump is Right: GOP Debate Audience is Packed Full of Republican Donors
2.FOX Con-Artists Use Unnecessary Censorship To Make Trump Sound Like He Said 'F*ck'
3.75-Yr-Old German Grandmother Tells of Sexual Harassment by Migrants, Interview Gets Interrupted by Clueless "Integrated" Muslim Teens
4.'End of Europe': Trump Slams Merkel's Refugee Policy, Wants Good Relations With Russia
5.EPA Rule to Ban Car Modification
6.New 'Traffic Violations Agency' Brings Buffalo Extortion Racket to All Time High
7.NYPD Cop Who Retired With Knee Injury, $66G Pension Regularly Runs Triathlons
8.Government Agents Hunt Woman Down After Seeing Facebook Picture Of Her Rehabilitating Baby Squirrels
Why does Gleevec, a leukemia drug that costs $70,000 per year in the United States, cost just $2,500 in India?
It's seemingly simple. Gleevec is under patent in the U.S., but not in India. Accordingly, Novartis, its Swiss-based manufacturer, may prevent competitors from making and selling lower-cost versions of the drug in the U.S., but not in India.